Hims & Hers and Noom Launch Peptide Programs After HHS Policy Shift

Two of America’s largest telehealth companies have entered the peptide market, signaling a major shift in consumer health and wellness. Hims & Hers (NYSE: HIMS) launched its Peptides+ offering on November 18, 2026, while rival Noom announced its own peptide program. Both moves followed a new U.S. Department of Health and Human Services (HHS) enforcement discretion policy issued in late October.

Under the new policy, championed by Secretary Robert F. Kennedy Jr., qualifying compounding pharmacies, licensed physicians, and federal facilities are permitted to compound six previously restricted peptides:

  • BPC-157
  • TB-500
  • KPV
  • MOTS-c
  • Epitalon
  • Semax

These short-chain amino acids have gained popularity among wellness enthusiasts seeking potential benefits such as muscle recovery, increased energy, enhanced libido, and anti-aging effects.

The announcements mark a pivotal moment for the peptide industry. Hims & Hers has a market capitalization of more than $3.5 billion, while Noom is privately valued at $3.7 billion. For Noom, the peptide offering extends the company’s reach beyond weight management into the broader longevity and wellness market.

The expansion has also drawn controversy. The American Medical Association (AMA) has criticized the HHS decision as “rushed,” noting that many of these compounded peptides have not been approved by the FDA or validated through randomized controlled clinical trials for safety and efficacy in humans.

Medical experts continue to raise safety concerns and urge consumers to consult with their doctors before beginning any peptide regimen.

Source: STAT News – “Peptide market poised to explode with new Hims and Noom launches” (November 19, 2026)

Move to the category:

Leave a Reply

Your email address will not be published. Required fields are marked *